Thus, blocking the PD-1/PD-L1 axis can lead to a range of synergistic antitumor effects: restoring tumor-specific T cell function, reducing tumor glycolysis, and improving glucose availability to T cells in the TME. The gene discussed is CD274; the disease is neoplasm.